症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022

doi:10.3969/j.issn.1673-5765.2022.08.013

摘要/Abstract

关键词: 颅内动脉粥样硬化性狭窄; 颅内动脉粥样硬化性疾病; 缺血性卒中; 血管内治疗; 抗血小板; 球囊扩张; 支架; 共识; 指南

中国卒中学会神经介入分会. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J]. 中国卒中杂志, 2022, 17(08): 863-888.

Chinese Stroke Association, Chinese Interventional Neuroradiology Society. Chinese Experts Consensus on Endovascular Treatment for Symptomatic Intracranial Atherosclerotic Stenosis 2022[J]. Chinese Journal of Stroke, 2022, 17(08): 863-888.

参考文献

[1] QURESHI A I，CAPLAN L R. Intracranial atherosclerosis[J]. Lancet，2014，383（9921）：984-998.
[2] WANG Y J，ZHAO X Q，LIU L P，et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China：the Chinese intracranial atherosclerosis（CICAS）study[J]. Stroke，2014，45（3）：663-669.
[3] KERNAN W N，OVBIAGELE B，BLACK H R，et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke，2014，45（7）：2160-2236.
[4] DERDEYN C P，CHIMOWITZ M I，LYNN M J，et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis（SAMMPRIS）：the final results of a randomised trial[J]. Lancet，2014，383（9914）：333-341.
[5] ZAIDAT O O，FITZSIMMONS B F，WOODWARD B K，et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis：the VISSIT randomized clinical trial[J]. JAMA，2015，313（12）：1240-1248.
[6] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2022-05-10]. https://doi.org/10.1161/str.0000000000000375.
[7] GUYATT G H，OXMAN A D，VIST G E，et al. GRADE：an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ，2008，336（7650）：924-926.
[8] BALSHEM H，HELFAND M，SCHUNEMANN H J，et al. GRADE guidelines：3. rating the quality of evidence[J]. J Clin Epidemiol，2011，64（4）：401-406.
[9] QURESHI A I，FELDMANN E，GOMEZ C R，et al. Intracranial atherosclerotic disease：an update[J]. Ann Neurol，2009，66（6）：730-738.
[10] HOLMSTEDT C A，TURAN T N，CHIMOWITZ M I. Atherosclerotic intracranial arterial stenosis：risk factors，diagnosis，and treatment[J]. Lancet Neurol，2013，12（11）：1106-1114.
[11] HURFORD R，WOLTERS F J，LI L X，et al. Prevalence，predictors，and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke：a population-based cohort study[J]. Lancet Neurol，2020，19（5）：413-421.
[12] LENG X Y，HURFORD R，FENG X Y，et al. Intracranial arterial stenosis in Caucasian versus Chinese patients with TIA and minor stroke：two contemporaneous cohorts and a systematic review[J]. J Neurol Neurosurg Psychiatry，2021，92（6）：590-597.
[13] QURESHI A I，ZIAI W C，YAHIA A M，et al. Stroke-free survival and its determinants in patients with symptomatic vertebrobasilar stenosis：a multicenter study[J]. Neurosurgery，2003，52（5）：1033-1040.
[14] CHIMOWITZ M I，LYNN M J，HOWLETT-SMITH H，et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis[J]. N Engl J Med，2005，352（13）：1305-1316.
[15] SANGHA R S，NAIDECH A M，CORADO C，et al. Challenges in the medical management of symptomatic intracranial stenosis in an urban setting[J]. Stroke，2017，48（8）：2158-2163.
[16] HURFORD R，WOLTERS F J，LI L，et al. Prevalence，predictors，and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke：a population-based cohort study[J]. Lancet Neurol，2020，19（5）：413-421.
[17] MCDOWELL F，FLAMM E S. EC/IC bypass study[J]. Stroke，1986，17（1）：1-2.
[18] CHIMOWITZ M I，LYNN M J，DERDEYN C P，et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis[J]. N Engl J Med，2011，365（11）：993-1003.
[19] WABNITZ A M，DERDEYN C P，FIORELLA D J，et al. Hemodynamic markers in the anterior circulation as predictors of recurrent stroke in patients with intracranial stenosis[J]. Stroke，2018，50（1）：143-147.
[20] PADALIA A，SAMBURSKY J A，SKINNER C，et al. Percutaneous transluminal angioplasty with stent placement versus best medical therapy alone in symptomatic intracranial arterial stenosis：a best evidence review[J/OL]. Cureus，2018，10（7）：e2988[2022-05-10]. https://doi.org/10.7759/cureus.2988.
[21] WONG K S，CHEN C，FU J H，et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis（CLAIR study）：a randomised，open-label，blinded-endpoint trial[J]. Lancet Neurol，2010，9（5）：489-497.
[22] LIU L P，WONG K S，LENG X Y，et al. Dual antiplatelet therapy in stroke and ICAS：subgroup analysis of CHANCE[J]. Neurology，2015，85（13）：1154-1162.
[23] KWON S U，CHO Y J，KOO J S，et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis：the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis[J]. Stroke，2005，36（4）：782-786.
[24] UCHIYAMA S，SAKAI N，TOI S，et al. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis（CATHARSIS）[J]. Cerebrovasc Dis Extra，2015，5（1）：1-13.
[25] UCHIYAMA S，TOYODA K，OMAE K，et al. Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis[J/OL]. J Am Heart Assoc，2021，10（20）：e022575[2022-05-10]. https://doi.org/10.1161/jaha.121.022575.
[26] AMARENCO P，ALBERS G W，DENISON H，et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin：a subgroup analysis of SOCRATES，a randomised，double-blind，controlled trial[J]. Lancet Neurol，2017，16（4）：301-310.
[27] JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[28] AMARENCO P，DENISON H，EVANS S R，et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin[J]. Stroke，2020，51（12）：3504-3513.
[29] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
[30] CHATURVEDI S，TURAN T N，LYNN M J，et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis[J]. Neurology，2007，69（22）：2063-2068.
[31] TURAN T N，NIZAM A，LYNN M J，et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial[J]. Neurology，2017，88（4）：379-385.
[32] AMIN-HANJANI S，TURAN T N，DU X，et al. Higher stroke risk with lower blood pressure in hemodynamic vertebrobasilar disease：analysis from the VERITAS study[J]. J Stroke Cerebrovasc Dis，2017，26（2）：403-410.
[33] PARK J M，KIM B J，KWON S U，et al. Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis：a result of randomized trial[J]. J Hypertens，2018，36（9）：1936-1941.
[34] AMARENCO P，BOGOUSSLAVSKY J，CALLAHAN A，et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med，2006，355（6）：549-559.
[35] AMARENCO P，GOLDSTEIN L B，SZAREK M，et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack：the stroke prevention by aggressive reduction in cholesterol levels（SPARCL）trial[J]. Stroke，2007，38（12）：3198-3204.
[36] AMARENCO P，BENAVENTE O，GOLDSTEIN L B，et al. Results of the stroke prevention by aggressive reduction in cholesterol levels（SPARCL）trial by stroke subtypes[J]. Stroke，2009，40（4）：1405-1409.
[37] American Diabetes Association. Glycemic targets：standards of medical care in diabetes-2020[J/OL]. Diabetes Care，2020，43（Suppl 1）：S66-S76[2022-05-10]. https://doi.org/10.2337/dc20-s006.
[38] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华内分泌代谢杂志，2021，37（4）：311-398.
[39] GAO P，ZHAO Z W，WANG D M，et al. China angioplasty and stenting for symptomatic intracranial severe stenosis（CASSISS）：a new，prospective，multicenter，randomized controlled trial in China[J]. Interv Neuroradiol，2015，21（2）：196-204.
[40] STAPLETON C J，CHEN Y F，SHALLWANI H，et al. Submaximal angioplasty for symptomatic intracranial atherosclerotic disease：a meta-analysis of peri-procedural and long-term risk[J]. Neurosurgery，2020，86（6）：755-762.
[41] SUNDT T M，SMITH H C，CAMPBELL J K，et al. Transluminal angioplasty for basilar artery stenosis[J]. Mayo Clin Proc，1980，55（11）：673-680.
[42] MIAO Z R，FENG L，LI S M，et al. Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents：long-term follow-up at a single center[J]. Neurosurgery，2009，64（1）：79-75.
[43] PARK S，KIM J H，KWAK J K，et al. Intracranial stenting for severe symptomatic stenosis：self-expandable versus balloon-expandable stents[J]. Interv Neuroradiol，2013，19（3）：276-282.
[44] LEUNG T W，MAK H，YU S C，et al. Perforator stroke after elective stenting of symptomatic intracranial stenosis[J]. Neurology，2007，68（15）：1237.
[45] SHIN Y S，KIM B M，SUH S H，et al. Wingspan stenting for intracranial atherosclerotic stenosis：clinical outcomes and risk factors for in-stent restenosis[J]. Neurosurgery，2013，72（4）：596-604.
[46] MIAO Z R，ZHANG Y，SHUAI J，et al. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China[J]. Stroke，2015，46（10）：2822-2829.
[47] WANG Z L，GAO B L，LI T X，et al. Outcomes of middle cerebral artery angioplasty and stenting with Wingspan at a high-volume center[J]. Neuroradiology，2016，58（2）：161-169.
[48] BAI W X，GAO B L，LI T X，et al. Wingspan stenting can effectively prevent long-term strokes for patients with severe symptomatic atherosclerotic basilar stenosis[J]. Interv Neuroradiol，2016，22（3）：318-324.
[49] ZHAO T，ZHU W Y，XIONG X Y，et al. Safety and efficacy of Wingspan stenting for severe symptomatic atherosclerotic stenosis of the middle cerebral artery：analysis of 278 continuous cases[J]. J Stroke Cerebrovasc Dis，2016，25（10）：2368-2372.
[50] BAIK S H，KWAK H S，CHUNG G H，et al. Balloon-expandable stents for treatment of symptomatic middle cerebral artery stenosis：clinical outcomes during long-term follow-up[J]. Interv Neuroradiol，2018，24（6）：666-673.
[51] ALEXANDER M J，ZAUNER A，CHALOUPKA J C，et al. WEAVE trial：final results in 152 on-label patients[J]. Stroke，2019，50（4）：889-894.
[52] ALEXANDER M J，ZAUNER A，GUPTA R，et al. The WOVEN trial：Wingspan one-year vascular events and neurologic outcomes[J]. J Neurointerv Surg，2021，13（4）：307-310.
[53] WANG T，YANG K，LUO J，et al. Outcomes after stenting for symptomatic intracranial arterial stenosis：a systematic review and meta-analysis[J]. J Neurol，2020，267（3）：581-590.
[54] LI G Z，YAN P，ZHAO Y Y，et al. A retrospective study comparison between stenting and standardized medical treatment for intracranial vertebrobasilar stenosis in a real-world Chinese cohort[J/OL]. Front Neurol，2021，12：629644[2022-05-10]. https://doi.org/10.3389/fneur.2021.629644.
[55] MOHAMMADEN M H，NOGUEIRA R G，TEKLE W，et al. Safety and efficacy of balloon-mounted stent in the treatment of symptomatic intracranial atherosclerotic disease：a multicenter experience[J]. J Neurointerv Surg，2022，14（8）：756-761.
[56] GAO P，WANG T，WANG D，et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis：the CASSISS randomized clinical trial[J]. JAMA，2022，328（6）：534-542.
[57] CHO S H，JO W I，JO Y E，et al. Bench-top comparison of physical properties of 4 commercially-available self-expanding intracranial stents[J]. Neurointervention，2017，12（1）：31-39.
[58] KRISCHEK O，MILOSLAVSKI E，FISCHER S，et al. A comparison of functional and physical properties of self-expanding intracranial stents[J]. Minim Invasive Neurosurg，2011，54（1）：21-28.
[59] VAJDA Z，SCHMID E，GUTHE T，et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent[J]. Neurosurgery. 2012，70（1）：91-101.
[60] FENG Z Z，DUAN G L，ZHANG P，et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis：an initial experience of 44[J/OL]. BMC Neurol，2015，15：187[2022-05-10]. https://doi.org/10.1186/s12883-015-0443-9.
[61] LEE K Y，CHEN D Y，HSU H L，et al. Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise：evaluation of clinical and vascular outcome[J]. Interv Neuroradiol，2016，22（2）：187-195.
[62] WANG X F，WANG Z G，WANG C W，et al. Application of the Enterprise stent in atherosclerotic intracranial arterial stenosis：a series of 60 cases[J]. Turk Neurosurg，2016，26（1）：69-76.
[63] DU Z H，MANG J，YU S Y，et al. Weighing in on the off-label use：initial experience of neuroform EZ stenting for intracranial arterial stenosis in 45 patients[J/OL]. Front Neurol，2018，9：852[2022-05-10]. https://doi.org/10.3389/fneur.2018.00852.
[64] SALIK A E，SELCUK H H，ZALOV H，et al. Medium-term results of undersized angioplasty and stenting for symptomatic high-grade intracranial atherosclerotic stenosis with Enterprise[J]. Interv Neuroradiol，2019，25（5）：484-490.
[65] XU H，QUAN T，ZAIDAT O O，et al. Neuroform EZ stenting for symptomatic intracranial artery stenosis：30 days outcomes in a high-volume stroke center[J/OL]. Front Neurol，2019，10：428[2022-05-10]. https://doi.org/10.3389/fneur.2019.00428.
[66] MEYER L，LEISCHNER H，THOMALLA G，et al. Stenting with acclino（flex）for symptomatic intracranial stenosis as secondary stroke prevention[J]. J Neurointerv Surg，2020，12（11）：1127-1131.
[67] SUN B W，XU C，WU P，et al. Intracranial angioplasty with Enterprise stent for intracranial atherosclerotic stenosis：a single-center experience and a systematic review[J/OL]. Biomed Res Int，2021，2021：6645500[2022-05-10]. https://doi.org/10.1155/2021/6645500.
[68] ZHOU K，CAO Y，HE X H，et al. A comparison of safety and effectiveness between Wingspan and Neuroform stents in patients with middle cerebral artery stenosis[J/OL]. Front Neurol，2021，12：527541[2022-05-10]. https://doi.org/10.3389/fneur.2021.527541.
[69] LI H，ZHANG L，WANG P，et al. The safety and efficacy of the Neuroform EZ stent for the treatment of symptomatic atherosclerotic stenosis in the middle cerebral artery[J/OL]. Clin Imaging，2022，82：210-215[2022-05-10]. https://doi.org/10.1016/j.clinimag.2021.11.024.
[70] HIGASHIDA R T，TSAI F Y，HALBACH V V，et al. Transluminal angioplasty for atherosclerotic disease of the vertebral and basilar arteries[J]. J Neurosurg，1993，78（2）：192-198.
[71] TOUHO H. Percutaneous transluminal angioplasty in the treatment of atherosclerotic disease of the anterior cerebral circulation and hemodynamic evaluation[J]. J Neurosurg，1995，82（6）：953-960.
[72] TAKIS C，KWAN E S，PESSIN M S，et al. Intracranial angioplasty：experience and complications[J]. AJNR Am J Neuroradiol，1997，18（9）：1661-1668.
[73] MARKS M P，MARCELLUS M，NORBASH A M，et al. Outcome of angioplasty for atherosclerotic intracranial stenosis[J]. Stroke，1999，30（5）：1065-1069.
[74] ALAZZAZ A，THORNTON J，ALETICH V A，et al. Intracranial percutaneous transluminal angioplasty for arteriosclerotic stenosis[J]. Arch Neurol，2000，57（11）：1625-1630.
[75] NAHSER H C，HENKES H，WEBER W，et al. Intracranial vertebrobasilar stenosis：angioplasty and follow-up[J]. AJNR Am J Neuroradiol，2000，21（7）：1293-1301.
[76] GUPTA R，SCHUMACHER H C，MANGLA S，et al. Urgent endovascular revascularization for symptomatic intracranial atherosclerotic stenosis[J]. Neurology，2003，61（12）：1729-1735.
[77] CONNORS J J，WOJAK J C. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions：evolution of technique and short-term results[J]. J Neurosurg，1999，91（3）：415-423.
[78] MARKS M P，WOJAK J C，AL-ALI F，et al. Angioplasty for symptomatic intracranial stenosis：clinical outcome[J]. Stroke，2006，37（4）：1016-1020.
[79] SIDDIQ F，VAZQUEZ G，MEMON M Z，et al. Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases：a multicenter study[J]. Stroke，2008，39（9）：2505-2510.
[80] QURESHI A I，CHAUDHRY S A，SIDDIQ F，et al. A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis[J]. J Vasc Interv Neurol，2013，6（2）：34-41.
[81] OKADA H，TERADA T，TANAKA Y，et al. Reappraisal of primary balloon angioplasty without stenting for patients with symptomatic middle cerebral artery stenosis[J]. Neurol Med Chir（Tokyo），2015，55（2）：133-140.
[82] DUMONT T M，SONIG A，MOKIN M，et al. Submaximal angioplasty for symptomatic intracranial atherosclerosis：a prospective Phase I study[J]. J Neurosurg，2016，125（4）：964-971.
[83] VILLWOCK M R，PADALINO D J，RAMASWAMY R，et al. Primary angioplasty versus stenting for endovascular management of intracranial atherosclerotic disease following acute ischemic stroke[J]. J Vasc Interv Neurol，2016，9（1）：1-6.
[84] WANG Y，MA Y，GAO P，et al. Primary angioplasty without stenting for symptomatic，high-grade intracranial stenosis with poor circulation[J]. AJNR Am J Neuroradiol，2018，39（8）：1487-1492.
[85] SEYEDSAADAT S M，YOLCU Y U，NEUHAUS A，et al. Submaximal angioplasty in the treatment of patients with symptomatic ICAD：a systematic review and meta-analysis[J]. J Neurointerv Surg，2020，12（4）：380-385.
[86] PENG G G，LI K Y，WANG A X，et al. Medical and endovascular treatments for intracranial atherosclerotic stenosis：a network meta-analysis[J/OL]. Transl Stroke Res，2021[2022-05-10]. https://doi.org/10.1007/s12975-021-00957-7.
[87] 李伟，姜卫剑，王拥军，等. 不同压力和不同扩张直径球囊对血管壁的影响[J]. 中国卒中杂志，2006，1（1）：23-26.
[88] BANGALORE S，KUMAR S，FUSARO M，et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents：a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials[J]. Circulation，2012，125（23）：2873-2891.
[89] ABOU-CHEBL A，BASHIR Q，YADAV J S. Drug-eluting stents for the treatment of intracranial atherosclerosis：initial experience and midterm angiographic follow-up[J/OL]. Stroke，2005，36（12）：e165-168[2022-05-10]. https://doi.org/10.1161/01.str.0000190893.74268.fd.
[90] GUPTA R，AL-ALI F，THOMAS A J，et al. Safety，feasibility，and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation[J]. Stroke，2006，37（10）：2562-2566.
[91] QURESHI A I，KIRMANI J F，HUSSEIN H M，et al. Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis[J]. Neurosurgery，2006，59（5）：1044-1051.
[92] FIELDS J D，PETERSEN B D，LUTSEP H L，et al. Drug eluting stents for symptomatic intracranial and vertebral artery stenosis[J]. Interv Neuroradiol，2011，17（2）：241-247.
[93] VAJDA Z，AGUILAR M，GOHRINGER T，et al. Treatment of intracranial atherosclerotic disease with a balloon-expandable paclitaxel eluting stent：procedural safety，efficacy and mid-term patency[J]. Clin Neuroradiol，2012，22（3）：227-233.
[94] GRUBER P，GARCIA-ESPERON C，BERBERAT J，et al. Neuro Elutax SV drug-eluting balloon versus Wingspan stent system in symptomatic intracranial high-grade stenosis：a single-center experience[J/OL]. J Neurointerv Surg，2018，10（12）：e32[2022-05-10]. https://doi.org/10.1136/neurintsurg-2017-013699.
[95] HAN J，ZHANG J，ZHANG X，et al. Drug-coated balloons for the treatment of symptomatic intracranial atherosclerosis：initial experience and follow-up outcome[J]. J Neurointerv Surg，2019，11（6）：569-573.
[96] YE G F，YIN X L，YANG X M，et al. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease：a systematic review and meta-analysis[J/OL]. J Clin Neurosci，2019，59：112-118[2022-05-10]. https://doi.org/10.1016/j.jocn.2018.10.118.
[97] HASSAN A E，MOHAMMADEN M H，RABAH R R，et al. Initial experience with the next-generation resolute Onyx Zotarolimus-Eluting stent in symptomatic intracranial atherosclerotic disease[J/OL]. Front Neurol，2020，11：570100[2022-05-10]. https://doi.org/10.3389/fneur.2020.570100.
[98] JIA B，ZHANG X，MA N，et al. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis：a randomized clinical trial[J]. JAMA Neurol，2022，79（2）：176-184.
[99] BEARD D J，LI Z J，SCHNEIDER A M，et al. Rapamycin induces an eNOS（endothelial nitric oxide synthase）dependent increase in brain collateral perfusion in wistar and spontaneously hypertensive rats[J]. Stroke，2020，51（9）：2834-2843.
[100] WANG J X，LIN X J，MU Z H，et al. Rapamycin increases collateral circulation in rodent brain after focal ischemia as detected by multiple modality dynamic imaging[J]. Theranostics，2019，9（17）：4923-4934.
[101] SUN J，KANG X，LI T. Vascular restoration：is there a window of opportunity?[J]. Med Hypotheses，2015，85（6）：972-975.
[102] KASTRATI A，JONER M，KUFNER S. What treatment should we dare in patients with in-stent restenosis?[J]. JACC Cardiovasc Interv，2018，11（3）：284-286.
[103] BAAN J，CLAESSEN B E，DIJK K B，et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis：the DARE trial[J]. JACC Cardiovasc Interv，2018，11（3）：275-283.
[104] DERDEYN C P，FIORELLA D，LYNN M J，et al. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty and stenting in the SAMMPRIS trial（stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis）[J]. Stroke，2017，48（6）：1501-1506.
[105] LEVY E I，TURK A S，ALBUQUERQUE F C，et al. Wingspan in-stent restenosis and thrombosis：incidence，clinical presentation，and management[J]. Neurosurgery，2007，61（3）：644-651.
[106] ALBUQUERQUE F C，LEVY E I，TURK A S，et al. Angiographic patterns of Wingspan in-stent restenosis[J]. Neurosurgery，2008，63（1）：23-28.
[107] ZAIDAT O O，CASTONGUAY A C，FITZSIMMONS B F，et al. Design of the vitesse intracranial stent study for ischemic therapy（VISSIT）trial in symptomatic intracranial stenosis[J]. J Stroke Cerebrovasc Dis，2013，22（7）：1131-1139.
[108] SCHWARTZ R S，HENRY T D. Pathophysiology of coronary artery restenosis[J/OL]. Rev Cardiovasc Med，2002，3（Suppl 5）：4-9[2022-05-10]. https://www.imrpress.com/journal/RCM/3/S5/pii/15615167 46306-886455059.
[109] TURK A S，LEVY E I，ALBUQUERQUE F C，et al. Influence of patient age and stenosis location on wingspan in-stent restenosis[J]. AJNR Am J Neuroradiol，2008，29（1）：23-27.
[110] SSYLVIA Study Investigators. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries（SSYLVIA）：study results[J]. Stroke，2004，35（6）：1388-1392.
[111] MA N，ZHANG Y，SHUAI J，et al. Stenting for symptomatic intracranial arterial stenosis in China：1-year outcome of a multicentre registry study[J]. Stroke Vasc Neurol，2018，3（3）：176-184.
[112] GRÖSCHEL K，SCHNAUDIGEL S，PILGRAM S M，et al. A systematic review on outcome after stenting for intracranial atherosclerosis[J/OL]. Stroke，2009，40（5）：e340-347[2022-05-10]. https://doi.org/10.1161/strokeaha.108.532713.
[113] JIN M，FU X，WEI Y Z，et al. Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis[J]. Stroke，2013，44（11）：2990-2994.
[114] HAIDEGGER M，KNEIHSL M，NIEDERKORN K，et al. Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis[J/OL]. Sci Rep，2021，11（1）：15599[2022-05-10]. https://doi.org/10.1038/s41598-021-95135-y.
[115] GUO X，MA N，GAO F，et al. Long-term risk factors for intracranial in-stent restenosis from a multicenter trial of stenting for symptomatic intracranial artery stenosis registry in China[J/OL]. Front Neurol，2020，11：601199[2022-05-10]. https://doi.org/10.3389/fneur.2020.601199.
[116] JIA Q，YAN S X. The short- and long-term efficacy of intravascular stenting in the treatment of intracranial artery stenosis[J]. Am J Transl Res，2021，13（6）：7115-7123.
[117] ZHANG Y，SUN Y J，LI X，et al. Early versus delayed stenting for intracranial atherosclerotic artery stenosis with ischemic stroke[J]. J Neurointerv Surg，2020，12（3）：274-278.
[118] GAO P，WANG D，ZHAO Z，et al. Multicenter prospective trial of stent placement in patients with symptomatic high-grade intracranial stenosis[J]. AJNR Am J Neuroradiol，2016，37（7）：1275-1280.
[119] LIEBESKIND D S，COTSONIS G A，SAVER J L，et al，Warfarin-aspirin symptomatic intracranial disease i. collaterals dramatically alter stroke risk in intracranial atherosclerosis[J]. Ann Neurol，2011，69（6）：963-974.
[120] AMIN-HANJANI S，PANDEY D K，ROSE-FINNELL L，et al. Effect of hemodynamics on stroke risk in symptomatic atherosclerotic vertebrobasilar occlusive disease[J]. JAMA Neurol，2016，73（2）：178-185.
[121] YAGHI S D，KHATRI P，PRABHAKARAN S，et al. What threshold defines penumbral brain tissue in patients with symptomatic anterior circulation intracranial stenosis：an exploratory analysis[J]. J Neuroimaging，2019，29（2）：203-205.
[122] ZHANG Y，RAJAH G B，LIU P，et al. Balloon-mounted versus self-expanding stents for symptomatic intracranial vertebrobasilar artery stenosis combined with poor collaterals[J]. Neurol Res，2019，41（8）：704-713.
[123] SUN X，TONG X，LO W T，et al. Risk factors of subacute thrombosis after intracranial stenting for symptomatic intracranial arterial stenosis[J]. Stroke，2017，48（3）：784-786.
[124] SUN L L，ZHANG J P，SONG Y，et al. Safety and efficacy of prophylactic tirofiban infusion for acute intracranial intraprocedural stent thrombosis[J/OL]. Sci Rep，2021，11（1）：21326[2022-05-10]. https://doi.org/10.1038/s41598-021-00872-9.
[125] SUN L，ZHANG J，SONG Y，et al. Safety and efficacy of tirofiban in rescue treatment for acute intracranial intraprocedural stent thrombosis[J/OL]. Front Neurol，2020，11：492[2022-05-10]. https://doi.org/10.3389/fneur.2020.00492.